DOP2010000201A - Derivado de 17-(1' - propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamentos que lo contienen - Google Patents

Derivado de 17-(1' - propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamentos que lo contienen

Info

Publication number
DOP2010000201A
DOP2010000201A DO2010000201A DO2010000201A DOP2010000201A DO P2010000201 A DOP2010000201 A DO P2010000201A DO 2010000201 A DO2010000201 A DO 2010000201A DO 2010000201 A DO2010000201 A DO 2010000201A DO P2010000201 A DOP2010000201 A DO P2010000201A
Authority
DO
Dominican Republic
Prior art keywords
derivatives
oxidoestra
propenil
ona
derived
Prior art date
Application number
DO2010000201A
Other languages
English (en)
Inventor
Hans-Peter Muhn
Ulrich Klar
Rolf Bohlmann
Katja Prelle
Steffen Borden
Frederik Menges
Joachim Kuhnke
Jan Hubner
Sven Ring
Thomas Frenzel
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40679349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2010000201(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of DOP2010000201A publication Critical patent/DOP2010000201A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/001—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class spiro-linked
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/007—3 membered carbocyclic rings in position 6-7

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La invención se refiere a derivados de 17e(1epro- penil)-17-3eoxidoestra--4-en-3-ona que tienen la fórmula química general I, en la cual Z, R4, R6a, R6b, R7, R5, Rl6a, Rl6b y R8 tienen los valores que se indican en la reivindi- cación 1, así como sus solvatos, hidratos y sales, incluyen- do todos los estereoisómeros de estos compuestos. La inven- ción también se refiere al uso de estos derivados para la preparación de un medicamento para la contracepción oral y para el tratamiento de trastornos pre, peri y posmeno- páusicos y a medicamentos que contienen tales derivados, particularmente su uso en las indicaciones mencionadas. Los derivados de la invención presentan un efecto gestagénico y en casos preferidos, adicionalmente un efecto antimineralcorticoide y neutro a ligeramente androgénico.
DO2010000201A 2007-12-29 2010-06-29 Derivado de 17-(1' - propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamentos que lo contienen DOP2010000201A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007063500A DE102007063500A1 (de) 2007-12-29 2007-12-29 17-(1'-Propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
DOP2010000201A true DOP2010000201A (es) 2010-07-15

Family

ID=40679349

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2010000201A DOP2010000201A (es) 2007-12-29 2010-06-29 Derivado de 17-(1' - propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamentos que lo contienen

Country Status (23)

Country Link
US (1) US9034856B2 (es)
EP (1) EP2238147B1 (es)
JP (1) JP5600069B2 (es)
KR (1) KR20100102190A (es)
CN (1) CN101918426A (es)
AR (1) AR069964A1 (es)
AU (1) AU2008342912A1 (es)
BR (1) BRPI0822068A2 (es)
CA (1) CA2710934C (es)
CL (1) CL2008003885A1 (es)
CR (1) CR11541A (es)
DE (1) DE102007063500A1 (es)
DO (1) DOP2010000201A (es)
EC (1) ECSP10010316A (es)
ES (1) ES2397985T3 (es)
IL (1) IL206381A0 (es)
MX (1) MX2010007269A (es)
PA (1) PA8807901A1 (es)
PE (1) PE20091185A1 (es)
TW (1) TW200940562A (es)
UY (1) UY31582A1 (es)
WO (1) WO2009083268A2 (es)
ZA (1) ZA201005397B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1183500B (de) 1962-10-12 1964-12-17 Schering Ag Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe
CH559220A5 (es) 1970-03-06 1975-02-28 Ciba Geigy Ag
US3705179A (en) 1971-03-15 1972-12-05 American Home Prod Antiandrogenic steroids
US3764596A (en) * 1971-06-22 1973-10-09 Sandoz Ag 17-dihydrofuranyl-substituted steroids
NL7701384A (nl) 1977-02-10 1978-08-14 Akzo Nv Werkwijze voor het bereiden van nieuwe steroiden van de oestraanreeks.
DE2922500A1 (de) 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
DE3402329A1 (de) 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
DE3702383A1 (de) 1987-01-23 1988-08-04 Schering Ag 11ss-alkinylestrene und -estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE4232521A1 (de) 1992-09-22 1994-03-24 Schering Ag Gestagen wirksame 4,5;11,12-Estradiene, Verfahren zu ihrer Herstellung, diese Estradiene enthaltende Arzneimittel sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19651000A1 (de) 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
DE102004063864A1 (de) 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
MX2010007269A (es) 2010-10-15
PA8807901A1 (es) 2009-07-23
EP2238147B1 (de) 2012-10-24
AR069964A1 (es) 2010-03-03
WO2009083268A2 (de) 2009-07-09
AU2008342912A1 (en) 2009-07-09
IL206381A0 (en) 2010-12-30
CA2710934A1 (en) 2009-07-09
DE102007063500A1 (de) 2009-07-02
UY31582A1 (es) 2009-08-03
EP2238147A2 (de) 2010-10-13
ECSP10010316A (es) 2010-08-31
ZA201005397B (en) 2012-01-25
ES2397985T3 (es) 2013-03-12
JP2011507925A (ja) 2011-03-10
PE20091185A1 (es) 2009-09-06
CR11541A (es) 2010-08-05
CA2710934C (en) 2015-07-21
TW200940562A (en) 2009-10-01
CN101918426A (zh) 2010-12-15
WO2009083268A3 (de) 2009-09-24
JP5600069B2 (ja) 2014-10-01
CL2008003885A1 (es) 2010-05-07
US20100317632A1 (en) 2010-12-16
BRPI0822068A2 (pt) 2015-06-23
US9034856B2 (en) 2015-05-19
KR20100102190A (ko) 2010-09-20

Similar Documents

Publication Publication Date Title
SV2004001690A (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos
UY30314A1 (es) Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmacéuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
UY30977A1 (es) Derivados de isoindolinas 4' -o-sustituidas. composiciones que las contienen y metodos para sus usos.
SV2008003032A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
UY31712A1 (es) Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmacéuticas que los contienen
PA8803201A1 (es) Derivados acidos de cicloalquilamino
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
EA200970849A1 (ru) Трициклические производные изохинолина для лечения ожирения
UY29883A1 (es) Nuevos beta-agonistas que contienen indol, procedimientos para prepararlos, y su empleo como medicamentos
CL2008001559A1 (es) Compuestos heterociclos que contienen al menos un atomo de nitrogeno, moduladores de gamma secretasa; composiciones farmaceuticas que los comprenden; uso de los compuestos en la preparacion de medicamentos para tratar trastornos del sistema nervioso central, tal como alzheimer; y kit que incluye a la composicion farmaceutica.
ECSP066331A (es) Compuestos de sulfonamidas derivados de benzoxazinona, su preparación y uso comun como medicamentos
UY31146A1 (es) Derivado de 17b-ciano-19-nor-androst-4-eno, su uso y medicamento que lo contiene
ECSP10010317A (es) Derivado 15,16-metilen-17-(1'-propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamento que lo contiene
DOP2010000201A (es) Derivado de 17-(1' - propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamentos que lo contienen
DOP2010000198A (es) Derivado de y-lactona del esteroide del acido 17-hidroxi-19-nor-21-carboxilico, su uso y medicamento que lo contiene
ECSP10010319A (es) Derivado de -lactona de esteroide de ácido 15,16-metilen-17-hidroxi-19-nor-21-carboxílico, su uso y medicamentos que contienen tal derivado
CU20100138A7 (es) Derivados de 17-(1'-propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamentos que lo contienen
CU20100140A7 (es) Derivados de 15,16-metilen-17-(1'-propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamento que lo contiene
DOP2010000199A (es) Derivados de 19-nor-esteroide que tiene, un grupo 15a, 16a-metileno y un anillo de 17,17- espirolactona saturado, su uso y medicamentos que los comprenden
CU20100141A7 (es) Derivados de ganma-lactona del esteroide del ácido 17-hidroxi-19-nor-21-carboxílico, su uso y el medicamento que lo contiene
CU20100139A7 (es) Derivados de y-lactona de esteroide de ácido 15,16-metilen-17-hidroxi-19-nor-21-carboxílico, su uso y medicamentos que contienen tal derivado
PA8777501A1 (es) Combinación de antagonista del receptor de progesterona con antiestrógenos no esteroidales para usar en enfermedades mediadas por brca
CL2009001113A1 (es) Compuestos derivados de 4,5-diarilpirrol-2-carboxamida; procedimiento de preparacion de estos; composicion farmaceutica que los comprende; uso en el tratamiento y/o prevencion de trastornos psiquiatricos, dependencia a sustancias, entre otras.
TH104953A (th) อนุพันธ์ 17-(1'-โพรพีนิล)-17-3'-ออกซิโดเอสตรา-4-อีน-3-โอน, การใช้อนุพันธ์ดังกล่าว และผลิตภัณฑ์ยาที่มีอนุพันธ์
DOP2004001045A (es) Derivados de indano heterrociclicos sustituido y compuesto relacionados para el tratamiento de la esquizofrenia